Navigation Links
Yashoda Cancer Institute Treats First Patient in India Using RapidArc Radiotherapy Technology
Date:4/20/2009

HYDERABAD, India, April 20 /PRNewswire/ -- Clinicians in India have carried out the country's first treatment using a new, faster form of radiotherapy that extends more advanced care to more patients. A 72-year-old bladder cancer patient received the pioneering treatment using RapidArc radiotherapy technology from Varian Medical Systems (NYSE: VAR) at Yashoda Cancer Institute in Hyderabad.

Varian's RapidArc technology makes it possible to deliver image-guided IMRT (intensity modulated radiotherapy) two to eight times faster than is possible with conventional IMRT. RapidArc delivers a precise and efficient treatment in single or multiple arcs of the treatment machine around the patient and offers several advantages over traditional approaches, according to clinician Dr. Srinivas Chilikuri.

"The whole treatment duration including set-up and check was completed in ten minutes, which involved just 90 seconds of 'beam-on' time," said Dr. Chilikuri. "We witnessed high dose conformity, excellent target coverage and good critical tissue sparing but the main advantage was the speed of the treatment."

Dr. Chilikuri said speed is particularly important because of the large number of cancer patients in India. "In a country like ours with a heavy cancer burden there is a real issue with waiting lists," he said. "We deal with this by prioritising and optimizing treatment facilities and RapidArc is an excellent example of this approach. With this, we can carry out faster and more precise treatments with less complex delivery and less complicated quality assurance requirements.

"The whole point of acquiring RapidArc was to treat more and more patients with high precision technology. With RapidArc's fast and efficient treatment delivery we will significantly increase the number of patients treated
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2012)... 23, 2012) The British Association for Psychopharmacology ... methods to treat substance abuse and addiction in ... SAGE. A panel of experts has carefully researched ... review of the evidence to help them optimise ... target treatment of substance abuse, harmful use, addiction ...
(Date:5/23/2012)... shows that phthalates from PVC flooring materials is taken ... cause asthma and allergies, as well as other chronic ... ingest these softening agents with food but also by ... group of chemical compounds that occur in construction materials ... as toys, cleaning solvents, packaging, etc. Phthalates are suspected ...
(Date:5/23/2012)... suggests that young asthma patients who use drugs known ... could be more likely than others to suffer from ... risk was not seen for some types of anticholinergics. ... recent interest in use of anticholinergics in asthma," study ... Chicago, said in a news release from the American ...
(Date:5/23/2012)... 23 (HealthDay News) -- The use of physical ... a multi-pronged approach that includes more training and ... to a new German study. Despite legal ... restraints such as bed rails and belts still ... survey found that the rate of physical-restraint use ...
(Date:5/23/2012)... ATS 2012, SAN FRANCISCO Prior treatment with ... develop community acquired pneumonia (CAP) is associated with ... according to a new study from researchers in ... of pleural effusion (excess fluid that accumulates between ... surrounds the lungs) that arises as a result ...
Breaking Medicine News(10 mins):Health News:British experts update addiction treatment guidelines 2Health News:Phthalates in PVC floors taken up by the body in infants 2Health News:Asthma Meds May Be Linked to Irregular Heartbeat 2Health News:Study Offers Ways to Decrease Use of Restraints at Nursing Homes 2Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2
... getting a princess' treatment in jail following her undisclosed medical ... living in 'Lean Cuisine' style sleeping comfortably and eating roast ... would never get. ,The jailbird has recently been ... Lynwood, California, from a Los Angeles jail hospital and is ...
... carnation and herb salad, nasturtium sauce -- Paris' top cooks ... ,"Flowers have been used for centuries in the ... culinary historian Patrick Rambourg told AFP. "In the Middle Ages ... banquets to perfume the room." , ,Ancient recipes from ...
... a law to ban circuses from importing or exporting ... animal rights, a legislator said Friday . ... all imports and exports of animals such as lions, ... needed for research, said Tien Chiu-chin, of the ruling ...
... between alcohol, drugs and risky sexual behaviour are providing ... government advisory body report said Friday . ... the last 12 years, and media coverage of celebrities' ... Advisory Group on Sexual Health and HIV said. ...
... 357 cases in 2006, bringing the total number of people diagnosed ... ,The 2006 figures released Friday on the ministry's website ... 317 new cases -- then a record high number of new ... ,More than 90 percent of new HIV cases detected in ...
... killed over 100 people last year in Sierra Leone's capital ... . ,A senior health worker attributed the fall ... by veterinary officials. Doctors at the main referral Connaught Hospital ... dog bites. ,The hospital has had to rely ...
Other Medicine News:Health News:Flower-power on a Plate in Paris 2Health News:Drink and Drugs 'fuel British Sexual Health Crisis' 2
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... WIRE) -- July 06, 2007 ... target="_blank" href=,'http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB"%3EDORB'>,http://studio.financialcontent.com/Engine?Account=iwire&PageName=QUOTE&Ticker=DORB">DORB ),("DOR" or the ... European Patent,Office has granted a ... claims related to,oral vaccination using ...
... Lancet on TMC125, an Investigational NNRTI,from Tibotec, ... Data from two,ongoing Phase 3 studies (DUET-1 ... with documented non-nucleoside reverse,transcriptase inhibitor (NNRTI) and ... load (defined as achieving,confirmed undetectable level < ...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
... choice of two feature-packed projectors ideal for any ... bulb for longer life -- up to 2,000 ... offers a lower initial cost with an incandescent ... bulb life. And both provide exceptionally even illumination ...
... modernized optical design and utilizes a multi-layered, ... producing a measurable 20% increase in optical ... of the Ultra Series also results in ... 15% expanded field of view and a ...
With the touch of a button, the Marco Encore Automatic Chair quickly reclines from an upright position to a fully horizontal, flat-table mode-or anywhere in between....
... the Marco Keratometer I and ... instruments for objectively measuring corneal ... the added feature of internal ... or those who prefer to ...
Medicine Products: